ArticleNature medicine2018
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Abstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 242 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed, 1 pooled it
16.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
242 citing papers in PubMed, 1 synthesis or guideline pooled it, 365 citations in OpenAlex.
- Dichotomous role of Shp2 for naïve and primed pluripotency maintenance in embryonic stem cells.Stem cell research & therapy · 2022Pooled it
- SHP-2 Expression Is a Positive Prognostic Biomarker in Non-Small-Cell Lung Carcinoma: Association with KRAS Mutation and Prolonged Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies.Journal of translational medicine · 2026Review
- Posttranslational modifications remodel proteome-wide ligandability.Nature chemical biology · 2026Article
- Article
- Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation.Journal of the American Chemical Society · 2026Review
- Article
- Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations.Signal transduction and targeted therapy · 2026Article
- Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.Molecular cancer research : MCR · 2026Article
- Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer.International journal of biological sciences · 2026Review
- Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition.Molecular & cellular proteomics : MCP · 2025Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk.Antioxidants (Basel, Switzerland) · 2025Review
- Allosteric SHP2 inhibitors suppress lung cancer cell migration by inhibiting non-canonical activation of EphA2 via the ERK-RSK signaling pathway.Scientific reports · 2025Article
- Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.Chinese medical journal · 2025Review
- Adagrasib in the treatment of colorectal cancer.Future oncology (London, England) · 2025Review
- SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.EMBO molecular medicine · 2025Article
- Literature review of advances and challenges inTranslational lung cancer research · 2025Review
- Deep mutational scanning of the multi-domain phosphatase SHP2 reveals mechanisms of regulation and pathogenicity.Nature communications · 2025Article
182 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 7 institutions in 3 countries.
Dietrich A RuessMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-4371-2246
Guus J HeynenCancer Research Program, Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Society, Berlin, Germany.
Katrin J CiecielskiMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Jiaoyu AiMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Alexandra BerningerMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Derya KabacaogluMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Kivanc GörgülüMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-1613-1422
Zahra DantesMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Sonja M WörmannMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Kalliope N DiakopoulosMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Angeliki F KarpathakiMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Marlena KowalskaMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Ezgi Kaya-AksoyMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Liang SongMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Eveline A Zeeuw van der LaanCancer Research Program, Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Society, Berlin, Germany.ORCID http://orcid.org/0000-0002-2784-5236
María P López-AlbercaMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Marc NazaréMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Maximilian ReichertMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Dieter SaurMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Mert M ErkanKoç University School of Medicine, Istanbul, Turkey.
Ulrich T HoptDepartment of Surgery, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany.
Bruno SainzDepartment of Biochemistry, Autónoma University of Madrid, School of Medicine, Instituto de Investigaciones Biomédicas "Alberto Sols", Madrid, Spain.
Walter BirchmeierCancer Research Program, Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Society, Berlin, Germany.
Roland M SchmidMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Marina LesinaMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Hana AlgülMildred-Scheel-Chair of Tumor Metabolism, Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. hana.alguel@mri.tum.de.
TUM Klinikum · DEMax Delbrück Center · DELeibniz-Forschungsinstitut für Molekulare Pharmakologie · DEInstituto de Investigaciones Biomédicas Sols-Morreale · ESKoç University · TRUniversity Medical Center Freiburg · DEUniversity of Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors
Indexed as
AnimalsCarcinogenesisCell Line, TumorDisease ProgressionHumansLung NeoplasmsMiceMitogen-Activated Protein Kinase KinasesMutationPancreatic NeoplasmsProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)Hras protein, mouseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)Ptpn11 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.